MARKET

URGN

URGN

Urogen Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.99
+0.64
+3.69%
Closed 16:00 05/11 EDT
OPEN
17.02
PREV CLOSE
17.35
HIGH
18.55
LOW
17.00
VOLUME
89.72K
TURNOVER
--
52 WEEK HIGH
30.89
52 WEEK LOW
17.00
MARKET CAP
401.15M
P/E (TTM)
-3.0431
1D
5D
1M
3M
1Y
5Y
Drug Delivery Devices Market 2020 Current Trends, Growth Prospects, Applications, Market Drivers, Key Players, Competitive Landscape, Opportunities & Geographical Analysis till 2025
May 07, 2021 (The Expresswire) -- Driving factors for the Market Drug delivery devices market includes medical devices that inject drugs and chemicals into...
The Express Wire · 4d ago
UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report first quarter 2021 financial results on Thursda...
BusinessWire · 5d ago
Bender Robert & Associates Buys Vertex Pharmaceuticals Inc, UroGen Pharma, Clovis Oncology ...
GuruFocus News · 04/28 17:38
DJ UroGen Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/27 10:44
DJ UroGen Pharma Price Target Cut to $50.00/Share From $57.00 by HC Wainwright & Co.
Dow Jones · 04/27 10:44
Urogen Pharma (URGN) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma (URGN) today and set a price target of $50.00. The company's shares closed
SmarterAnalyst · 04/27 10:25
Stifel Nicolaus Reaffirms Their Buy Rating on Urogen Pharma (URGN)
Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Urogen Pharma (URGN) today. The company's shares closed last Wednesday at $19.71.
SmarterAnalyst · 04/21 20:55
Overactive Bladder Treatment Market 2027 by Investment Feasibility, Sales, Production and Company Introduction
Apr 10, 2021 (Market Insight Reports) -- Global Overactive Bladder Treatment Market Overactive bladder is a common medical condition, in which there arises a...
Market Insight Reports · 04/10 07:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of URGN. Analyze the recent business situations of Urogen Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average URGN stock price target is 38.00 with a high estimate of 51.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 119
Institutional Holdings: 18.21M
% Owned: 81.65%
Shares Outstanding: 22.30M
TypeInstitutionsShares
Increased
25
245.30K
New
10
359.12K
Decreased
26
460.64K
Sold Out
8
567.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
Arie Belldegrun
President/Chief Executive Officer/Director
Elizabeth Barrett
Chief Financial Officer/Chief Accounting Officer
Molly Henderson
Executive Vice President
Marina Konorty
Executive Vice President
Jim Ottinger
Chief Compliance Officer/General Counsel
Jason Smith
Other
Jeff Bova
Other
Polly Murphy
Other
Mark Schoenberg
Other
Elyse Seltzer
Independent Director
Cynthia Butitta
Independent Director
Fred Cohen
Independent Director
Kathryn Falberg
Independent Director
Stuart Holden
Independent Director
Ran Nussbaum
Independent Director
Shawn Tomasello
No Data
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Webull offers kinds of Urogen Pharma Ltd stock information, including NASDAQ:URGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, URGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading URGN stock methods without spending real money on the virtual paper trading platform.